Louisville, Colorado-based GlobeImmune, the developer of biopharmaceuticals aimed at treating cancer and infectious diseases, filed for an IPO Tuesday, saying it is looking to raise up to $69M on the NASDAQ Global Market.
GlobeImmune files for IPO